A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (CANTOR)
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Volrustomig (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CANTOR
- Sponsors AstraZeneca
- 03 Feb 2025 New trial record